|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 23, 2017 ) Browse 91 market data tables and 30 figures spread through 148 pages and in-depth TOC on "Human Microbiome Market"
http://www.marketsandmarkets.com/Market-Reports/human-microbiome-market-37621904.html
Early buyers will receive 10% customization on this report.
Rising aging population, increasing incidences of lifestyle diseases, gradual demand for efficient and safe medication with no side effects, and treatment of diseases having a limited success rate are driving the growth of the human microbiome market.
The human microbiome market is an emerging market with abundant opportunities and is expected to flourish within five to seven years owing to a number of products currently under the clinical trial phase. In this report, the global human microbiome market is divided into three major segments namely, application, disease, and product.
Get The PDF Brochure For This Report:
http://www.marketsandmarkets.com/pdfdownload.asp?id=37621904
The factors restraining the human microbiome market include lack of comprehensive research to assist in market pull, lack of awareness among the population regarding the efficient usage and effect of prebiotics and probiotics, and impending government regulations on probiotics and prebiotics.
Europe is expected to command as a resourceful market with the largest share in the human microbiome market and expected to grow within the coming years. This is due to Europe’s aging population size and the increasing lifestyle diseases, followed by the increasing need to stay fit and have a healthy lifestyle has leveraged the use of prebiotics and probiotics. APAC accounted for the second-largest market share and will be the main focus of the market in the coming five years that will register high-growth rates for all the segments.
Download Sample Pages:
http://www.marketsandmarkets.com/requestsample.asp?id=37621904
The key players in the market are Enterome Bioscience (France), Yakult Honsha Co., Ltd. (Japan), E. I. Du Pont de Nemours and Company (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences, Inc. (U.S.), Osel, Inc. (U.S.), and Merck & Co, Inc. (U.S.)
About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: 1-888-600-6441
MarketsandMarkets
Mr. Rohan
1-888-600-6441
sales@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
